|Pluristem Scientists to Present a Poster on GvHD; Cannabis Companies Continue To Ramp Up Operations|
|By Staff and Wire Reports|
|Tuesday, 25 March 2014 20:57|
Pluristem Therapeutics, Inc. ($PSTI +1.32% (tase:PLTR), a leading developer of placenta-based cell therapies, today announced its participation in the 2nd UK-Israel Regenerative Medicine Conference (BIRAX), which is being held on March 25 and 26, 2014 in Haifa at the Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology.
Ohad Karnieli, Pluristem's Vice President of Development & Manufacturing will be a panelist on a session focused on commercialization of regenerative medicine titled, "Road to Clinical Translation - The viewpoint from Industry," on March 26th, at 4:20 pm.
Shani Raveh, Ph.D., Pluristem's Scientist will present a scientific poster titled, "Prevention of GvHD by PLX-PAD Cells via intravenous (IV) or intramuscular (IM) Administration". Preliminary results from Pluristem's preclinical study of its Placental eXpanded cells (PLX) in the prevention of graft versus host disease (GvHD) were announced in October, 2013. Dr. Raveh will present this data. Conclusions of the preclinical study include:
a) PLX-PAD administration mitigates GvHD symptoms, suggesting that it may be an effective and novel prophylactic treatment for GvHD; and
b) The beneficial effect of PLX-PAD is achieved by both IM and IV routes of administration implying that the systemic effect can be achieved also by local administration.
DirectView Holdings, Inc. (OTCQB: DIRV) announced that its wholly owned subsidiary DirectView Security's plans to open a Colorado office to support the expansion of its cannabis industry security and surveillance business. The Company expects establish an office at Legacy Construction Company of Colorado's office complex beginning in April 2014.
DirectView Security will initially staff two sales professionals to work with Legacy as well as other potential partners and customers in Colorado and the surrounding areas. Management believes the establishment of a physical office in Colorado will enable the company to capitalize on the growing number of opportunities in the region's cannabis industry for its video surveillance and security offerings as well as alarm monitoring and access control.
3D Systems (NYSE:DDD) today announced that its ProJet® 3510 MP 3D printer and proprietary VisiJet® Stoneplast dental materials are now also available for use with 3Shape Implant Studio™, allowing dental professionals to output accurate and fully functional dental implant drill guides that are designed using the 3Shape Implant Studio software.
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 third quarter financial results for the period ended February 28, 2014, on Wednesday, April 9, 2014, after the close of the U.S. financial markets.
BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of results, in the American Heart Journal, of an analysis of aggregated data from three large, multicenter clinical research trials in the United States and Europe.
Body Central Corp. (Nasdaq:BODY) today announced financial results for the fourth quarter of 2013.
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2013.
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, announced today that its HIV 1/2 STAT-PAK® Assay received CE Mark approval from European regulators.
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today its financial results and business highlights for the fourth quarter and full year 2013.
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and twelve-month period ended December 31, 2013, after the close of the market on Monday, March 31, 2014.
Endocyte, Inc. (Nasdaq:ECYT) announced today that it is offering to sell 4.5 million shares of its common stock in an underwritten public offering.
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended Dec. 31, 2013.
FutureWorld (OTCQB: FWDG), a U.S. Diversified Holding Company formed to capitalize on the burgeoning technology markets globally, announces today that HempTech is in discussion with manufacturers to build automated state-of-the-art medical dispensaries and storage machines for dispensing medicinal marijuana and CBD-based Pharmaceuticals & Nutraceuticals infused with edible consumable goods, like hard candies, granola, and other food products.
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its skin and wound product line with the introduction of Integra® Wound Matrix.
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013, and provided an update on corporate developments and upcoming events.
Mazor Robotics, Ltd. (TASE: MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced that for the first time ever, a surgeon utilized Mazor Robotics Renaissance Guidance System to perform an Asleep Deep Brain Stimulation (DBS) procedure earlier this month at Littleton Adventist Hospital in Littleton, Colo.
MedAssets (Nasdaq:MDAS) today announced that Baptist Health Care, a four-hospital health system and member of the Mayo Clinic Care Network, has signed a multi-year agreement that replaces its incumbent vendor for a wide array of the company's total cost management and operational efficiency solutions.
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, today announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of $14.00 per share.
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from seven clinical studies will be presented at the upcoming American College of Medical Genetics (ACMG) annual meeting, which will be held Mar. 25-Mar.29, 2013 in Nashville, Tennessee.
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that holistic and medical marijuana expert Dr. Mark L. Rabe, Chairman of the Scientific Advisory Board of Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., will deliver a significant presentation at the 2nd Annual National Medical Cannabis Unity Conference "Navigating Medical Cannabis in the Mainstream" that will be held in Washington, DC April 5-7, 2014.
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the Foundation Fighting Blindness (Foundation), a national nonprofit driving sight-saving research, will honor Sucampo's Co-Founder and Chairman Emeritus, Ryuji Ueno, M.D., Ph.D., Ph.D., with the Foundation's Visionary Award, in recognition of Dr. Ueno's longstanding commitment to helping patients with eye diseases. The 12th Annual D.C.
Vitacost.com, Inc. (Nasdaq:VITC), a leading online retailer of healthy living products, announced today that its Annual Meeting of Stockholders will be held on Thursday, June 5, 2014 in Boca Raton, Florida.